Trisomy 8 May Not Affect The Prognosis Of Certain MDS Patients
Published: Oct 2, 2012 2:08 pm
Results of a recent retrospective analysis conducted in Spain indicate that certain myelodysplastic syndromes patients with trisomy 8 may have a similar prognosis as patients without the chromosomal abnormality.
Specifically, the Spanish researchers found that myelodysplastic syndromes (MDS) patients with trisomy 8 and immature stem cell (blast) counts of less than 5 percent had similarly long overall survival times as patients without the chromosomal abnormality.
However, the researchers point out that additional larger studies are necessary to confirm their findings.
MDS patients frequently have abnormalities in their chromosomes, the structures where a person’s genetic information is stored. In some cases, there may be an extra copy of a chromosome (called a trisomy), whereas in others, small chromosomal sections or even entire chromosomes may be missing.
According to the Spanish researchers, a duplication in chromosome 8, also referred to as trisomy 8, is the most common duplication among MDS patients. MDS with trisomy 8 is currently classified as intermediate-risk MDS.
However, the Spanish researchers point out that previous studies have shown varying outcomes among MDS patients with trisomy 8. In addition, they mention that the impact of additional chromosomal abnormalities on outcomes of these patients has not been determined yet.
To shed more light on these issues and to determine the clinical features associated with trisomy 8, they retrospectively analyzed data from 134 MDS patients with trisomy 8 who were diagnosed in Spain between 1988 and 2011.
The median patient age was 72 years.
Approximately half of the patients (54 percent) had trisomy 8 alone, 23 percent had one additional chromosomal abnormality, 6 percent had two additional abnormalities, and 17 percent had three or more additional chromosomal abnormalities.
Most patients (94 percent) had received supportive care.
During a median follow-up time of 16 months, a quarter of patients progressed to acute myeloid leukemia.
The researchers found that patients with trisomy 8 alone was more likely to be male (67 percent) than female (33 percent).
The median blast count in patients with trisomy 8 alone was 4 percent, and 80 percent of patients had at least one low blood cell count.
They also found that the most common chromosomal abnormality in addition to trisomy 8 was a deletion in chromosome 5 (29 percent of patients), followed by a deletion in chromosome 11 (10 percent).
Overall survival was shorter for patients with trisomy 8, compared to those without the chromosomal abnormality.
Specifically, overall survival was 34 months for patients with trisomy 8 alone, 40 months for patients with trisomy 8 plus one additional chromosomal abnormality, 23 months for patients with trisomy 8 plus two additional chromosomal abnormalities, and 6 months for patients with trisomy 8 plus three or more additional chromosomal abnormalities. In comparison, overall survival was 99 months for MDS patients, who were diagnosed without chromosomal abnormalities in Spain during the same time period.
Among patients with trisomy 8 alone, the researchers found that those with blast counts of less than 5 percent had better overall survival (64 months) than those with a blast count of 5 percent or more (10 months). In fact, the overall survival of patients with trisomy 8 alone and a blast count of less than 5 percent was similar to that of patients without chromosomal abnormalities with the same blast count.
Platelet counts below 100 x 109/L also had a negative effect on survival.
The researchers point out that these survival results are better than those from previous studies, which they contribute to the fact that they did not include patients with blast counts of more than 20 percent or patients with chronic myelomonocytic leukemia in their analysis.
For more information, please see the study in the British Journal of Haematology (abstract).
- The Percent Of Abnormal Cells May Be An Indicator For Disease Prognosis In MDS Patients With Trisomy 8
- Trisomy 14 Is Not Linked To Poorer Prognosis In Myelodysplastic Syndromes Patients
- Having Additional Chromosomal Abnormalities May Be Linked To Poorer Prognosis In MDS Patients With Chromosome 5 Deletion
- Response To Anemia Drugs Linked To Prognosis In Lower-Risk MDS Patients
- Spanish Study Argues Monosomal Karyotype Does Not Independently Impact MDS Prognosis